medigraphic.com
SPANISH

Revista Médica de Costa Rica y Centroamérica

Colegio de Medicos y Cirujanos República de Costa Rica
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2010, Number 592

<< Back Next >>

Rev Med Cos Cen 2010; 67 (592)

Uso del sildenafila en pacientes con riesgo cardiovascular

Gómez VF
Full text How to cite this article

Language: Spanish
References: 20
Page: 107-114
PDF size: 521.35 Kb.


Key words:

No keywords

ABSTRACT

Sidenafil is an effective medicine which works for erectile dysfunction. From the very beginning, some anecdotal cases have been reported which suggested some kind of association between this medicine and coronary adverse effects. Several clinical essays have studied some of the negative effects from this drug in the cardiovascular system. Not even one research has reported an increment in the use of this medicine with coronary adverse effects. Princeton’s Consensus of Erectile Dysfunction and Cardiovascular Disease establishes the clinical guidance according to the real facts. It emphasize in the accurate patient’s stratification before starting or resuming sexual activity


REFERENCES

  1. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomised crossover trial. JAMA 2002;287:719-25.

  2. Canales JM, Bustamante F-Uso de sildenafil en hombres con cardiopatía coronaria: Consideraciones clínicas y epidemiológicas Revista Mexicana de Cardiología Abril-Junio 1999 Vol 10, Número 2 pp 85-89.

  3. Carson C. Cardiac Safety in Clinical Trials of Phosphodiesterase 5 Inhibitors. Am J Cardiol 2005; 96[suppl]:37M–41M)

  4. Cheitlin M, Cochair A, Hutter A, Brindis R, Ganz P, Kaul S, Russell R, Zusman R. ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273-82.

  5. Cheitlin M, Hutter AM, Brindis RG, Ganz P, Kaul S, Russel RO et al. Use of sildenafil in patients with cardiovascular disease: AHA/ACC Expert Consensus Document. J Am Coll Card 1999; 33: 273-82.

  6. Conti C, Pepine C, Sweeney M Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. American Journal of Cardiology, 1999, 83,Sup 1 29-34

  7. DeBusk R, Pepine C, Glasser D, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and Safety of Sildenafil Citratein Men With Erectile Dysfunction and Stable Coronary Artery Disease. Am J Cardiol 2004;93:147–153

  8. Drogo K. Montague, Jonathan P. Jarow, Gregory A. Broderick, Roger R. Dmochowski, Jeremy P.W. Heaton, Tom F. Lue, Aaron J. Milbank, Ajay Nehra, Ira D. Sharlip. American Urological Association. Management of Erectile Dysfunction. Chapter 1 with Appendix: Diagnosis and Treatment Guideline. 2005. Disponible en: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/edmgmt/chapter1.pdf año 2006

  9. Drory Y, Fisman EZ, Shapira Y, Puines A. Ventricular arrhythmia during sexual activity in patients with coronary artery disease. Chest 1996; 109: 992-4.

  10. Fink H, Mac Donald M, Rutks I,Nelson D,Wilt T. Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis Arch Intern Med 2002, 162; 1349

  11. Fox K, Thadani U, Ma P, Nash, Keating Z, Czorniak M, Gillies H, Keltai Mon Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina European Heart Journal (2003) 24, 2206–2212

  12. Guimarães A, Bolívar M, Rizzi O, Zilli E, Luna R. Use of Sildenafil in Patients with Cardiovascular Disease Arq Bras Cardiol 1999; 73: 38-42

  13. Halcox J, Nour K, Zalos G, Mincemoyer R, Waclawiw M. Rivera C et al. The Effect of Sildenafil on Human Vascular Function, Platelet Activation, and Myocardial Ischemia J Am Coll Cardiol, 2002; 40:1232-1240

  14. Herrmann H.C, Chang G, Klugherz B. D., Hemodinamic Effects of Sildenafil in Men with Severe Coronary Artery Disease. NEJM 2000, 342:1622-1626.

  15. Kloner Robert A.. Sex and the Patient with Cardiovascular Risk Factors: Focus on Sildenafil Am J Med. 2000;109(9A):13S–21S

  16. Kostis J, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett A, Carson C, Cheitlin M et al. Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference. Am J Cardiol 2005;96:313–321

  17. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003;57:597–600.

  18. Mittleman M, Maclure M, Glasser D. Evaluation of Acute Risk for Myocardial Infarction in Men Treated With Sildenafil Citrate Am J Cardiol 2005; 96: 443-446

  19. Olsson A. Sildenafil appears safe for men with cardiovascular disease but further study is recommended. Geriatrics; 2000;55: 69-70.

  20. Patrizi R, Leonardo F, Pelliccia F, Chierchia SL, Galetta P, Cerquetani E, et al. Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. Ital Heart J 2001; 2 (11): 841-844)




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med Cos Cen. 2010;67